 Kazia Therapeutics Ltd ASX:KZA, NASDAQ:KZIAs cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new study at Sunnybrook Health Sciences Centre in Toronto, Ontario. The companys flagship drug, paxalisib, is a candidate in GBM AGILE, a multi-drug platform study designed to identify promising new therapies for glioblastoma. 